In terms of NSCLC, a large comparative study of different genetic alterations demonstrated a significant prognostic benefit in ROS1 mutated tumors compared with other gene mutations (e.g., EGFR, KRAS) [25]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.